PARP inhibitors: The race is on

British Journal of Cancer

Volumn 114, Issue 7, 2016, Pages 713-715

  Brown, Jessica S ^a,b   Kaye, Stan B ^a,b   Yap, Timothy A ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; TALAZOPARIB; VELIPARIB; INDOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; BREAST NEOPLASMS; FEMALE; GENETICS; GERMLINE MUTATION; OVARIAN NEOPLASMS;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GERM-LINE MUTATION; HUMANS; INDOLES; OVARIAN NEOPLASMS;

EID: 84962082445     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.67     Document Type: Editorial

References (22)

1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
2. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R (2016) Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. In press
3. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson D a, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, Oconnor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, De Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
5. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, Ahern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JHM, De Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519.
6. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861.
7. Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5: 387-393.
8. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33: 244-250.
9. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30: 372-379.
10. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J ClinOncol 28: 3555-3561.
11. Kristeleit R, Swisher E, Oza A, Coleman R, Scott C, Konecny G, Tinker A, Omalley D, Brenton J, Bell-McGuinn K, Oaknin A, Leary A, Lin K, Raponi M, Giordano H, Maloney L, Goble S, Yelensky R, McNeish I (2015) Final results of ARIEL2 (Part 1): a phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Eur Cancer Congr 51: s531.
12. Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16: 110-120.
13. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu Y-M, Cao X, Brough R, Pemberton H, Ahern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, De Bono JS (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl JMed 373: 1697-1708.
14. Murai J, Huang SYN, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72: 5588-5599.
15. Oconnor MJ (2015) Targeting the DNA damage response in cancer. Mol Cell 60: 547-560.
16. Puhalla S, Beumer JH, Pahuja S, Appleman LJ, Abdul-Hassan Tawbi H, Stoller RG, Lee JJ, Lin Y, Kiesel B, Yu J, Tan AR, Belani CP, Chew HK, Garcia AA, Morgan R, Giranda VL, Peacock Shepherd S, Chen AP, Chu E (2014) Final results of a phase 1 study of single-Agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA?), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt) 2014 ASCO Annual Meeting. Abstracts Meeting Library. Available at http://meetinglibrary.asco.org/content/129661-144.
17. Rafii S, Gourley C, Ang JE, Kumar R, Geuna E, Rye T, Ashcroft L, Powell B, Shapira-Frommer R, Friedlander M, Chen L, Matulonis U, Kaufman B, De Greve J, Oza AM, Banerjee SN, Gore ME, Molife LR, Kaye SB, Yap TA (2015) What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?. 2015 ASCO Annual Meeting. Abstracts Meeting Library. Available at http://meetinglibrary.asco.org/content/149021-156.
18. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, De Bono JS, Wenham RM (2013) The poly(ADPribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. Lancet Oncol 14: 882-892.
19. Shen Y, Aoyagi-scharber M, Wang B (2015) Minireview Trapping Poly (ADP-Ribose) Polymerase. J Pharmacol Exp Ther 353(3): 446-457.
20. Telli ML, Timms K, Reid JE, Ford JM, Neff C, Abkevich V, Gutin A, Sangale Z, Illiev D, Jones JT, Hennessy B, Lanchbury JS, Mills GB, Hartman A-R, Ford JM (2015) Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triplenegative and/or BRCA1/2 mutation-Associated breast cancer. 2015 ASCO Annual Meeting. Abstracts Meeting Library. Available at http:// meetinglibrary.asco.org/content/150370-156.
21. Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Averett Byers L, Chugh R, Wade Goldman J, Sachdev JC, Matei DE, Wheler JJ, Henshaw JW, Zhang C, Gallant G, De Bono JS (2014) Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. 2014 ASCO Annual Meeting. Abstracts Meeting Library. Available at http://meetinglibrary.asco.org/content/128953-144.
22. Yap TA, Sandhu SK, Carden CP, De Bono JS (2011) Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61: 31-49.